Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group
- 10 July 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (20), 2372-2379
- https://doi.org/10.1200/jco.2015.65.3469
Abstract
Purpose Children’s Oncology Group study AHOD03P1 was designed to determine whether excellent outcomes can be maintained for patients with low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) with a strategy of resection alone or minimal chemotherapy. Patients and Methods Patients with stage IA LPHL in a single node that was completely resected were observed without further therapy; recurrences were treated with three cycles of doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC). Patients with unresected stage IA or stage IIA LPHL were treated with three cycles of AV-PC. Patients with less than a complete response (CR) to AV-PC received 21-Gy involved-field radiation therapy (IFRT). Results A total of 183 eligible patients were enrolled; 178 were evaluable. Of these, 52 patients underwent complete resection of a single node. There were 13 relapses at a median of 11.5 months; 5-year event-free survival (EFS) was 77% (range, 62% to 87%). A total of 135 patients received AV-PC; 126 were treated at diagnosis and nine at relapse after surgery alone. Eleven patients receiving AV-PC had less than CR and received IFRT. Fourteen first events occurred among 135 patients (12 relapses and two second malignancies). Two relapses occurred in patients who had received IFRT. Five-year EFS was 88.8% (95% CI, 81.8% to 93.2%). Five-year EFS for the entire cohort was 85.5% (95% CI, 79.2% to 90.1%); overall survival was 100%. Conclusion Some 75% of highly selected pediatric patients with LPHL may be spared chemotherapy after surgical resection alone. Pediatric LPHL has excellent EFS with chemotherapy that is less intensive than standard regimens; > 90% of patients can avoid radiation therapy. The salvage rate for the few relapses is high, with 100% survival overall.Keywords
This publication has 59 references indexed in Scilit:
- Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern EraInternational Journal of Radiation Oncology*Biology*Physics, 2015
- Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin LymphomaJournal of Clinical Oncology, 2014
- Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implicationsLaboratory Investigation, 2013
- Rituximab in Hodgkin lymphoma: Is the target always a hit?Cancer Treatment Reviews, 2010
- Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2010
- Resection alone in 58 children with limited stage, lymphocyte‐predominant Hodgkin lymphoma–experience from the European network group on pediatric Hodgkin lymphomaCancer, 2007
- Long‐term outcome after radiotherapy alone for lymphocyte‐predominant Hodgkin lymphomaCancer, 2005
- Second cancers following pediatric Hodgkin's disease.Journal of Clinical Oncology, 1998
- Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.Journal of Clinical Oncology, 1997
- Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's DiseaseNew England Journal of Medicine, 1996